225 results about "Cerebral damage" patented technology

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):

X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  I

• • or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

An alkyl ether derivative represented by the formula:

wherein R¹, R², R³, R⁴, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

The invention belongs to the technical field of medicine, and concretely relates to caffeoyl substituted pentacyclic triterpenoid derivatives as shown in a formula I and a purpose thereof in preparing medicaments or health products for preventing and treating brain injury and/or neurological dysfunction and/or cognitive dysfunction caused by cerebral ischemia, hypoglycemia and cerebral anoxia. Experiments verify that the derivatives is capable of protecting nerve cells under conditions of hypoglycemia and hypoxia, can substantially improve neurological damage induced by cerebral ischemia, and thus is expected to be developed as medicaments for preventing and treating the brain injury caused by the cerebral ischemia, the hypoglycemia and the cerebral anoxia as well as improving corresponding neuroethology functions.

The invention relates to the field of Chinese medicaments, in particular to a Chinese medicinal composition for preventing and treating ischemic brain injury, and a preparation method thereof. The Chinese medicinal composition for preventing and treating ischemic brain injury is an orally taken preparation prepared from extracts of raw astragalus roots, panax notoginseng, kudzuvine roots, baikal skullcap roots and gardenia serving as main active components, as well as pharmaceutical auxiliary materials. The preparation has obvious therapeutic effects on cerebral infarction convalescent symptoms of which the clinical manifestations are eye-mouth distortion, glossolalia, slobbering or hemiplegia, dark red tongue or yellow greasy tongue coating, weak or uneven pulse and the like.

The invention belongs to the medical rehabilitation equipment field, and relates to a digitlization simulation mirror image training system comprising a trainee interaction display, a trainee control platform, a host computer, a camera, sound equipment, digit mirror image training box hardware, a specially compiled space imagination training module, a basic motion training module, and a functional motion training module program system; the camera can film hand motion images; digitalized image mirror image equipment is formed by mirror image processing technology; the standard digitlization simulation mirror image treatment training system is provided; visual illusion and visual sense imagination can activate the cerebrum motion sense cortex zone, thus promoting limb motion functions and sense function recovery; optics imaging is converted into digit display, thus increasing mirror image treatment controllability and operationality, improving patient compliance, enriching mirror image training contents, regulating the training scheme enforcement procedure, and obtaining the optimized training effect; the digitlization simulation mirror image training system is suitable for rehabilitation training of hand function obstacles caused by brain damages, and finger cutting, affected limb aches, hand perception deletion or obstacles of hand operation patients.

The present invention relates to the identification and use of diagnostic markers related with brain damage, particularly, biomarkers independently selected from the group consisting of interleukin-17 (IL-17), Fas ligand (FasL), b nerve growth factor (bNGF), insulin growth factor binding protein 3 (IGFBP3), p55 tumour necrosis factor receptor (TNFR-1), growth-related oncogene alpha (GroA), interleukin-2 soluble receptor gamma (IL2RG) and combinations thereof, that are associated with the diagnosis, prognosis, or differentiation of stroke mimicking conditions and stroke in a subject.

The invention relates to a method for establishing an artery ischemia model of a brain of a rhesus monkey and an evaluation method. The constructing method adopts the mode of directly puncturing femoral arteries of an experimental monkey to perform the intravascular interventional operation under the direct view of a digital subtraction angiography, and establishes the chronic cerebral infarctionprimate model by using a micro-catheter to block the arteries in the brain of the experimental monkey and controlling ischemia time. The model is a quite reasonable cerebral ischemia-reperfusion animal model, and the pathological characteristics of the monkey cerebral injury model established by the method are similar to clinical manifestation; and moreover, the model is stable and reliable and issuitable for all kinds of curing therapeutic research and related basic research.

The present invention belongs to the field of pharmaceutical technology and relates to transdermal Ligustrazine plaster and its preparation. It has Ligustrazine phosphate or Ligustrazine as active medicinal component and consists of medicine storing back, adhering layer, release controlling film, back lining layer and protective layer. It is superior to available Ligustrazine preparation forms inmedicine releasing are, transdermal rate and lasting release time, and has the features of determined curative effect, stable quality, high safety, etc. Animal experiments show that the plaster can retard the effect of ischemic to cerebral damage, inhibit thrombosis caused by tissue damage, prevent and treat cerebral embolism and maintain balanced medicine density in blood for 24 hr; and has light irritation to skin, no irritability and no toxic reaction.

The invention discloses a comprehensive magnetic resonance imaging device. According to the invention, the cerebral function imaging, the MRI perfusion weighted imaging and the magnetic resonance diffusion imaging are united, so that the assessment for the cerebral injury caused by motor neuron disease and Parkinson disease is assisted, a beneficial judging basis is supplied for illness state judgment, and the accuracy rate of disease judgment is increased; an ALS (amyotrophic lateral sclerosis) patient is accompanied with FTD (frontal temporal dementia), so that the detection means, such as cortex thickness, also is beneficial to the disease diagnose and research; functional magnetic resonance imaging (fMRI) and diffusion tensor imaging techniques have strong complementarity; the combination of the functional magnetic resonance imaging and diffusion tensor imaging techniques has a wide application prospect in neurosciences research; unique brain structure and function information can be supplied.

The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided.

This invention relates to compositions and methods for diagnosing and treating concussion/mTBI.

NMR spectroscopy is used as an efficient and effective rapid screening method for identifying compounds that interact with PSD-95. This method includes the steps of taking a first NMR spectrum of a sample of free PDZ2; mixing a test compound with said sample of free PDZ2 to form a test sample; taking a second NMR spectrum of said test sample; and comparing said first and second spectra. An observable difference of the two spectra indicates that the test sample contains ingredient(s) capable of binding to the PDZ domains of PSD-95.

The invention discloses application of (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone in preparing a medicine for treating cerebrovascular diseases. The related research indicates that the compound has an obvious cranial nerve protection effect, obviously reduces the focal cerebral ischemia rat cerebral infarction volume and remarkably improves the neurologic symptom. The (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone is used for preventing or treating the diseases such as ischemic brain injury, cerebral hemorrhage, cerebral thrombosis, cerebral embolism, cerebral infarction, cerebral apoplexy, lacunar infarction, transient ischemic attack, cerebral arteriosclerosis, diabetic cerebrovascular complications and the like.

The invention discloses a preparation method and an application of human umbilical cord mesenchymal stem cells. The preparation method includes the steps of: performing asepsis treatment to umbilical cord of a full-term caesarean delivered healthy fetus, mechanically cutting the umbilical cord, digesting the umbilical cord through collagenase and performing separation cultivation. In about the third generation, cell shape becomes flat and broad and the cells grow well. The method can culture the cells till the 15th generation, wherein cell division phase is reduced and cytoplasm is loose, there are vacuoles in the cells, and cell aging and proliferation are significantly slowed, so that the third-generation cells have high activity and can be applied in subsequent researching and treatment. The human umbilical cord mesenchymal stem cells are used in therapy of cerebral injury, and improve function recovery after the cerebral injury.